4个月quabodepistat联合delamanid和bedaquiline方案治疗药物敏感肺结核:一项多中心、开放标签、随机、概念验证、非劣效性2b/c期试验
该研究在南非6个中心纳入122例新诊断药物敏感肺结核成人,随机接受4个月DBQ方案(quabodepistat三个剂量)或6个月标准RHEZ方案。DBQ总体耐受性良好。
要点
- 4个月DBQ方案在药物敏感肺结核中达到非劣效于6个月RHEZ的主要终点。
- DBQ组严重不良事件或导致停药的治疗相关事件未见报告。
- 研究支持quabodepistat作为缩短结核疗程方案的候选组分进一步研究。
核心结论
- 在概念验证试验中,4个月DBQ方案治疗结束时的痰培养阴转率非劣效于6个月RHEZ方案,且总体耐受性良好。
研究设计与样本
- 多中心、开放标签、随机、概念验证、非劣效性2b/c期试验,在南非6个临床研究中心开展。
- 招募18-65岁新诊断药物敏感肺结核成人,随机(1:2:2:1)分为DBQ10、DBQ30、DBQ90和RHEZ组。
- DBQ组接受口服delamanid 300 mg每日一次、bedaquiline 400 mg每日一次2周后200 mg每周三次,联合quabodepistat每日一次10/30/90 mg,疗程4个月;RHEZ组接受6个月标准方案。
- 主要终点为改良意向治疗(mITT)分析集中治疗结束时痰培养阴转比例和安全性分析集中的安全性;非劣效界值12%,采用双侧80%CI比较合并DBQ组与RHEZ组。
- 共筛查306人,入组122人,121人接受至少一剂研究药物并构成mITT分析集。
主要发现
- ≥3级不良事件发生率:DBQ10组20%(4/20)、DBQ30组14%(6/42)、DBQ90组11%(4/38)、RHEZ组5%(1/21)。
- 105/121(87%)参与者发生至少一次治疗中出现的不良事件;最常见为上呼吸道感染(30%)、头痛(20%)和腹泻(10%)。
- DBQ90组1例参与者在肺结核恶化合并肺炎后死亡,评估与治疗无关。
关键数值与推荐
- 非劣效界值为12%,采用双侧80%CI比较合并DBQ组与RHEZ组的主要终点。
临床怎么用
- 对于新诊断药物敏感肺结核成人,4个月DBQ方案显示出与6个月标准方案相似的痰培养阴转率,可作为未来缩短疗程研究的候选方案。
- DBQ方案总体耐受性良好,但需关注≥3级不良事件,尤其DBQ10组发生率20%。
- 当前证据来自2b/c期概念验证试验,尚不能用于临床常规实践。
局限性
- 开放标签设计,未对受试者和研究者设盲,仅微生物实验室人员设盲。
- 样本量较小,每组20-42例,且为概念验证阶段。
- 研究仅在南非6个中心开展,外部推广性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combined therapy with delamanid, bedaquiline, and quabodepistat (DBQ) showed potent early bactericidal activity and was well tolerated in a phase 2a, 14-day early bactericidal activity trial in participants with drug-susceptible pulmonary tuberculosis. This subsequent proof-of-concept trial evaluated the efficacy and safety of a 4-month, three-dose level regimen of DBQ in participants with drug-susceptible pulmonary tuberculosis compared with 6 months of the standard of care. METHODS: This open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial was conducted at six clinical research sites in South Africa. Adults aged 18-65 years with newly diagnosed, drug-susceptible pulmonary tuberculosis were recruited by research sites from community tuberculosis clinics. Participants were randomly assigned (1:2:2:1) by balanced block randomisation (block size six) to receive oral delamanid (300 mg once a day) and bedaquiline (400 mg once a day for 2 weeks then 200 mg three times a week) plus quabodepistat at once-daily doses of 10 mg (DBQ10 group), 30 mg (DBQ30 group), or 90 mg (DBQ90 group) for 4 months; or 6 months of RHEZ (rifampicin, isoniazid, ethambutol, and pyrazinamide for 8 weeks followed by 18 weeks of rifampin and isoniazid). All drugs were administered orally. Masking procedures were not used, although microbiology laboratory staff were masked to treatment assignment. The primary endpoints were the proportion of participants reaching sputum culture conversion by the end of the treatment period in the modified intention-to-treat (mITT) analysis set and safety in the safety analysis set. Non-inferiority, with a margin of 12%, was assessed for the primary endpoint in the mITT analysis set, comparing the pooled DBQ group and the RHEZ group using a two-sided 80% CI. This study was registered at ClinicalTrials.gov, NCT05221502, and is complete. FINDINGS: Between April 12, 2022, and May 19, 2024, 306 individuals were screened, of whom 122 were enrolled and randomly assigned: 20 to the DBQ10 group, 42 to the DBQ30 group, 39 to the DBQ90 group, and 21 to the RHEZ group. 121 participants received at least one dose of study drug and comprised the mITT analysis set. At the end of the treatment period, the proportion of participants with sputum culture conversion was 100·0% (95% CI 83·2-100·0, all 20 participants) in the DBQ10 group, 92·9% (80·5-98·5, 39 of 42 participants) in the DBQ30 group, 97·4% (86·2-99·9, 37 of 38 participants) in the DBQ90 group, 96·0% (90·1-98·9, 96 of 100 participants) in the pooled DBQ group, and 100·0% (83·9-100·0, all 21 participants) in the RHEZ group. The comparison between the pooled DBQ group and the RHEZ group met non-inferiority for the primary endpoint (difference -4·0% [80% CI -7·4 to 3·4]). Adverse events were mostly mild to moderate, with no serious adverse events or discontinuations attributed to trial medications. Rates of adverse events of grade 3 or higher were 20% (four of 20 participants) in the DBQ10 group, 14% (six of 42 participants) in the DBQ30 group, 11% (four of 38 participants) in the DBQ90 group, and 5% (one of 21 participants) in the RHEZ group. One participant (in the DBQ90 group) died after worsening pulmonary tuberculosis with pneumonia, which was assessed as not related to study treatment. 105 (87%) of 121 participants had at least one treatment-emergent adverse event: 17 (85%) of 20 in the DBQ10 group, 37 (88%) of 42 in the DBQ30 group, 30 (79%) of 38 in the DBQ90 group, and all 21 (100%) participants in the RHEZ group. The most common treatment-emergent adverse events in the total population of 121 participants were upper respiratory tract infection (n=36, 30%), headache (n=24, 20%), and diarrhoea (n=12, 10%). INTERPRETATION: In this proof-of-concept study, 4 months of DBQ showed a promising end-of-treatment non-inferiority signal versus 6 months of RHEZ and was generally well tolerated. Our results support further studies of quabodepistat as a potential component of new treatment-shortening regimens for tuberculosis. FUNDING: Otsuka Pharmaceutical Development & Commercialization, with partial funding from the Gates Foundation.
引用
- Dawson R, Diacon AH, Variava E, et al. Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial. Lancet Infect Dis. 2026. PMID: 42214407. doi:10.1016/S1473-3099(26)00143-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。